Sign in
Active, not recruitingNo phase

Lactoferrin in Treatment of Fe Deficient Anemia In Cirrhosis

Key facts

Who runs it
Post Graduate Institute of Medical Education and Research, Chandigarh
Where
India1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
130 people, planned
Started
1 Jan 2020
Expected to end
Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Lactoferrin + Iron Supplement
  • Iron Supplement
Record updated
13 November 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Age 18-75 years
  • Either gender
  • Patients with chronic liver disease with iron deficiency anemia with transferrin saturation<20% and Hemoglobin in Non-pregnant women (15 years of age and above) <12g/dl and in men <13g/dl -

Who cannot take part

  • Post liver transplant patients
  • Patients who are on psychoactive drugs, like sedatives or antidepressants
  • Severe preexisting cardiopulmonary disease
  • HIV infection
  • Renal dysfunction (S. Creatinine ≥ 2mg/dL)
  • Those who do not consent to participate in the study
  • Inability to obtain informed consent from patient or relatives
  • Pregnancy/Lactation
  • Patients who are too sick to carry out the protocol

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Iron deficiency and altered homeostasis due to inflammation and decreased iron utilization are main factors involved in anemia in liver disease. Lactoferrin is a first line defence protein for protection against microbial infections and subsequent development of systemic disease as seen with systemic inflammatory response syndrome (SIRS) and sepsis. Lactoferrin with iron has been shown to be efficacious with anemia in chronic disease, in pregnancy and in cancer patients with fewer side effects than oral iron alone. High exposure to iron is associated with increased inflammation which is associated with worse cardiovascular outcomes. Lactoferrin can help reduce the total iron dose and hepatic inflammation.

The 2 groups in the trial

  • Group A: Lactoferrin plus oral ironTreatment being tested

    Treated for 2 months regularly with oral administration of 100 mg Lactoferrin tablet twice a day before meals with oral administration of 100 mg of elemental iron capsules, one capsule twice daily on an empty stomach, at least 1 hour before or 2 hours after meals

    Treatment: Lactoferrin + Iron Supplement

  • Oral iron aloneExisting treatment, for comparison

    Oral administration of 100 mg of elemental iron capsules, one capsule twice daily on an empty stomach, at least 1 hour before or 2 hours after meals

    Treatment: Iron Supplement

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Lactoferrin With Iron Versus Iron Alone in Treatment of Anemia In Chronic Liver Disease
Record updated
13 November 2026